(Date:9/7/2008)... Byetta has also been linked recently to patient d...s) -- A new once-a-week formulation of the injecta... better than the older twice-a-day formulation, re...ase of use, [the new formulation] provided the rem...cose control and good gastrointestinal tolerabilit...
(Date:9/5/2008)... HARRISBURG, Pa., Sept. 5 /PRNewswire-USNewswire/ ... issued a proclamation acknowledging Sept. 11 as,A...lth of Pennsylvania and The American Red Cross ask...oration of those who lost their,lives on 9/11 and ...lood,donation can save up to three lives., "We al...
(Date:9/5/2008)...earchers explain how theoretical ,anti-cloak, coul..., Sept. 5 (HealthDay News) -- Just in case someone...se scientists say they know how to uncloak the obj... in Optics Express , certain materials underneath...ts to be seen again. , Researchers at Shanghai ...
(Date:9/5/2008)... FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthrosu...developer of less-invasive joint,resurfacing syste...he U.S.,FDA to begin its pivotal investigation for...FDA stated that "there are no outstanding safety,c...tiation., Arthrosurface has been evaluating the s...
Breaking Medicine News(10 mins):Health News:Once-Weekly Diabetes Drug Boosts Blood Sugar Control 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2(Date:9/6/2008)...cent or Greater Concordance Compared to FISH ... - Company to Include Reporting for HER2 Gene Expr...eports by End of 2008 -, REDWOOD CITY, Calif., Se...c. (Nasdaq: GHDX ) today announced results from t...ng for HER2 gene expression, as measured by the,co...
(Date:9/5/2008)...PRNewswire-USNewswire/ -- The Florida,Technology, ...orida,Atlantic University researcher Dr. Herbert W...the Center for Molecular Biology and,Biotechnology... CHS,Resources LLC (CHS), $184,294 as part of the ...ance Grant program (SURECAG). SURECAG was,establis...
(Date:9/5/2008)..., Sept. 5 /- SARcode,Corpor... LFA-1 inhibitors,to treat inflammatory diseases, ...oday announced SARcode,s initiation of a Phase 1 c...ndidate for T-cell mediated ophthalmic,diseases. S...t providing,SARcode with an exclusive license to S...
(Date:9/4/2008)... 4 /- Cytopia Limited (ASX:,CYT) toda...s Phase Ib/II,study of CYT997, the company,s novel... with an aggressive form of brain cancer known as ...trial is the first Phase II efficacy study in high...ny and the second in its,suite of Phase II studies...
Breaking Medicine Technology:Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3Medgate Selected by NASA to Deliver Health and Safety Software Solutions 23181 1Back From the Dead 3A Cardiac Arrest Victim Salutes His Rescuer 23177 1Back From the Dead 3A Cardiac Arrest Victim Salutes His Rescuer 23177 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 1Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 3New Hope Against the Cold Sore Virus 23170 1New Hope Against the Cold Sore Virus 23170 2New Hope Against the Cold Sore Virus 23170 3...--(BUSINESS WIRE)--Apr 18, 2007 - Gemin,X today an...ata,from a study of its lead compound, GX15-070 (o...(ALL). The study was discussed in an,oral presenta...tion,for Cancer Research (AACR). According to the ...ctivity against ALL blast cells,and also enhanced...
... WIRE)--Apr 18, 2007 - Idera,Pharmaceuticals, Inc....data for two new potential applications in oncolog...LR9) at the Annual Meeting of,the American Associa...Angeles, CA, April 14-18, 2007. The first presenta...lead oncology candidate,IMO-2055, in combination ...
Other Medicine Technology:Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 2Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 3Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR 4Transcranial vascular DWL doppler.
Transcranial vascular DWL doppler.
Transcranil vascular DWL doppler.
...m Viasys Neurocare is a full-featured physiologic ...table size. It contains many of the features of ou...t an economical price. , ,The smaller size of ...ironment, the physician's office, a mobile service...
Medicine Products: